HBM Holdings unit wins US$20.2 million jury verdict in U.S. patent infringement case against Amgen

• HBM Holdings reported a Delaware jury verdict against Amgen in a patent infringement case tied to its antibody discovery platform patents.
• Jury found infringement was willful, upheld patent validity, awarded damages of USD 20.2 million.
• Willfulness finding supports a bid for enhanced damages of up to triple, lifting the award to about USD 60.6 million.
• Trial began June 8, 2026; the lawsuit was filed in 2021.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. HBM Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260615-12201895), on June 15, 2026, and is solely responsible for the information contained therein.